Orbis Medicines Raises EUR 90 Million to Advance Next-Generation Oral Macrocycle Drugs

Orbis Medicines completes a EUR 90 million Series A funding round, appoints Morten Graugaard as CEO, and emphasizes the development of high-value oral alternatives to blockbuster biologic drugs.